BR112023023527A2 - Inibidores de nlrp3 - Google Patents
Inibidores de nlrp3Info
- Publication number
- BR112023023527A2 BR112023023527A2 BR112023023527A BR112023023527A BR112023023527A2 BR 112023023527 A2 BR112023023527 A2 BR 112023023527A2 BR 112023023527 A BR112023023527 A BR 112023023527A BR 112023023527 A BR112023023527 A BR 112023023527A BR 112023023527 A2 BR112023023527 A2 BR 112023023527A2
- Authority
- BR
- Brazil
- Prior art keywords
- nlrp3 inhibitors
- compounds
- nlrp3
- inhibitors
- methods
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 title 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21173452 | 2021-05-12 | ||
| EP21209447 | 2021-11-22 | ||
| EP21215859 | 2021-12-20 | ||
| PCT/EP2022/062525 WO2022238347A1 (en) | 2021-05-12 | 2022-05-10 | Nlrp3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023023527A2 true BR112023023527A2 (pt) | 2024-01-30 |
Family
ID=81941106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023023527A BR112023023527A2 (pt) | 2021-05-12 | 2022-05-10 | Inibidores de nlrp3 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20240208928A1 (https=) |
| EP (2) | EP4337652B1 (https=) |
| JP (1) | JP2024517917A (https=) |
| KR (1) | KR20240007152A (https=) |
| AR (1) | AR125818A1 (https=) |
| AU (1) | AU2022275300A1 (https=) |
| BR (1) | BR112023023527A2 (https=) |
| CA (1) | CA3214626A1 (https=) |
| CL (1) | CL2023003312A1 (https=) |
| CO (1) | CO2023016204A2 (https=) |
| CR (1) | CR20230529A (https=) |
| DK (1) | DK4337652T3 (https=) |
| ES (1) | ES3031704T3 (https=) |
| FI (1) | FI4337652T3 (https=) |
| HR (1) | HRP20250632T1 (https=) |
| HU (1) | HUE071498T2 (https=) |
| IL (1) | IL307188A (https=) |
| LT (1) | LT4337652T (https=) |
| MA (1) | MA64323B1 (https=) |
| MX (1) | MX2023012907A (https=) |
| PE (1) | PE20240126A1 (https=) |
| PL (1) | PL4337652T3 (https=) |
| RS (1) | RS66893B1 (https=) |
| SI (1) | SI4337652T1 (https=) |
| WO (1) | WO2022238347A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| IL314025A (en) * | 2022-01-07 | 2024-08-01 | Transthera Sciences Nanjing Inc | Nlrp3 inflammasome inhibitor and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| AU2023371859A1 (en) * | 2022-11-04 | 2025-06-12 | Transthera Sciences (Nanjing) , Inc. | Nlrp3 inflammasome inhibitor and use thereof |
| PE20251845A1 (es) * | 2022-12-07 | 2025-07-17 | Hoffmann La Roche | Compuestos novedosos como moduladores de la inhibicion de nlrp3 |
| WO2024158941A2 (en) * | 2023-01-27 | 2024-08-02 | Mwyngil Therapeutics, Inc. | Inhibitors of nlrp3 |
| JP2026511027A (ja) * | 2023-03-20 | 2026-04-10 | インシリコ メディスン アイピー リミティド | Ｎｌｒｐ３インフラマソーム阻害剤及びその使用 |
| WO2024193699A1 (zh) | 2023-03-23 | 2024-09-26 | 成都赜灵生物医药科技有限公司 | 三嗪类化合物及其用途 |
| KR20260027946A (ko) | 2023-06-02 | 2026-03-03 | 머크 샤프 앤드 돔 엘엘씨 | Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클 |
| IL324489A (en) | 2023-06-29 | 2026-01-01 | Hoffmann La Roche | Triazine derivatives as NLRP3 inhibitors |
| CN121586712A (zh) | 2023-07-28 | 2026-02-27 | 豪夫迈·罗氏有限公司 | 新颖化合物 |
| WO2025059069A1 (en) * | 2023-09-12 | 2025-03-20 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6653316B1 (en) * | 1999-05-19 | 2003-11-25 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
| AR119731A1 (es) * | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
-
2022
- 2022-05-10 AR ARP220101225A patent/AR125818A1/es unknown
- 2022-05-10 PL PL22728228.2T patent/PL4337652T3/pl unknown
- 2022-05-10 CA CA3214626A patent/CA3214626A1/en active Pending
- 2022-05-10 HU HUE22728228A patent/HUE071498T2/hu unknown
- 2022-05-10 EP EP22728228.2A patent/EP4337652B1/en active Active
- 2022-05-10 LT LTEPPCT/EP2022/062525T patent/LT4337652T/lt unknown
- 2022-05-10 JP JP2023569634A patent/JP2024517917A/ja active Pending
- 2022-05-10 HR HRP20250632TT patent/HRP20250632T1/hr unknown
- 2022-05-10 MX MX2023012907A patent/MX2023012907A/es unknown
- 2022-05-10 DK DK22728228.2T patent/DK4337652T3/da active
- 2022-05-10 MA MA64323A patent/MA64323B1/fr unknown
- 2022-05-10 RS RS20250561A patent/RS66893B1/sr unknown
- 2022-05-10 IL IL307188A patent/IL307188A/en unknown
- 2022-05-10 PE PE2023002971A patent/PE20240126A1/es unknown
- 2022-05-10 FI FIEP22728228.2T patent/FI4337652T3/fi active
- 2022-05-10 SI SI202230138T patent/SI4337652T1/sl unknown
- 2022-05-10 AU AU2022275300A patent/AU2022275300A1/en active Pending
- 2022-05-10 WO PCT/EP2022/062525 patent/WO2022238347A1/en not_active Ceased
- 2022-05-10 BR BR112023023527A patent/BR112023023527A2/pt unknown
- 2022-05-10 KR KR1020237038678A patent/KR20240007152A/ko active Pending
- 2022-05-10 ES ES22728228T patent/ES3031704T3/es active Active
- 2022-05-10 EP EP25167922.1A patent/EP4609865A3/en active Pending
- 2022-05-10 CR CR20230529A patent/CR20230529A/es unknown
-
2023
- 2023-11-07 CL CL2023003312A patent/CL2023003312A1/es unknown
- 2023-11-10 US US18/506,492 patent/US20240208928A1/en active Pending
- 2023-11-29 CO CONC2023/0016204A patent/CO2023016204A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023012907A (es) | 2023-11-08 |
| PL4337652T3 (pl) | 2025-07-14 |
| TW202311245A (zh) | 2023-03-16 |
| SI4337652T1 (sl) | 2025-07-31 |
| RS66893B1 (sr) | 2025-07-31 |
| EP4337652B1 (en) | 2025-04-09 |
| LT4337652T (lt) | 2025-06-25 |
| EP4609865A3 (en) | 2025-10-29 |
| KR20240007152A (ko) | 2024-01-16 |
| JP2024517917A (ja) | 2024-04-23 |
| DK4337652T3 (da) | 2025-06-10 |
| AR125818A1 (es) | 2023-08-16 |
| CA3214626A1 (en) | 2022-11-17 |
| AU2022275300A1 (en) | 2023-09-21 |
| MA64323B1 (fr) | 2025-06-30 |
| ES3031704T3 (en) | 2025-07-10 |
| EP4609865A2 (en) | 2025-09-03 |
| PE20240126A1 (es) | 2024-01-22 |
| EP4337652A1 (en) | 2024-03-20 |
| US20240208928A1 (en) | 2024-06-27 |
| FI4337652T3 (fi) | 2025-06-20 |
| HUE071498T2 (hu) | 2025-09-28 |
| WO2022238347A1 (en) | 2022-11-17 |
| HRP20250632T1 (hr) | 2025-07-18 |
| CR20230529A (es) | 2023-12-04 |
| IL307188A (en) | 2023-11-01 |
| CL2023003312A1 (es) | 2024-06-21 |
| CO2023016204A2 (es) | 2023-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023023527A2 (pt) | Inibidores de nlrp3 | |
| BR112023025318A2 (pt) | Derivados de triazina e seu uso no tratamento do câncer | |
| BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
| BR112023003580A2 (pt) | Compostos heterocíclicos | |
| CL2022001670A1 (es) | Inhibidores de proteínas kras mutantes | |
| BR112022011651A2 (pt) | Degradadores de irak e usos dos mesmos | |
| BR112023019797A2 (pt) | Inibidor derivado heterocíclico e método de preparação do mesmo e aplicação do mesmo | |
| BR112022003982A2 (pt) | Compostos heterocíclicos | |
| BR112022012410A2 (pt) | Degradadores smarca e usos dos mesmos | |
| BR112023023223A2 (pt) | Degradadores de cdk2 e usos dos mesmos | |
| BR112019006571A2 (pt) | derivados de éter de isoxazolila como gaba a alfa5 pam | |
| BR112022018828A2 (pt) | Derivados de benzodiazepina como gaba a gamma1 pams | |
| BRPI1009333B8 (pt) | compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| BR112021026899A2 (pt) | Compostos heterocíclicos | |
| BR112022003704A2 (pt) | Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl | |
| BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
| BR112014010644A2 (pt) | novos derivados de aril-quinolina | |
| MX2016002185A (es) | Formulacion combinada de dos compuestos antivirales. | |
| BR112022005472A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl), seus usos, processo de fabricação e composição farmacêutica | |
| BR112013018732A2 (pt) | novos derivados de amida de aril-benzocicloalquila | |
| BR112022003357A2 (pt) | Compostos heterocíclicos | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| CL2025001372A1 (es) | Derivados de triazinona como inhibidores de nlrp3. | |
| BR112022022608A2 (pt) | Compostos como inibidores de bcl-2 |